Acute Myeloid Leukemia Clinical Trial
— DECIDEROfficial title:
Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy
AML of the older patient constitutes a major unmet clinical need since the large majority will not be found eligible for induction chemotherapy. Reasons for this decision include host factors (comorbidities, reduced performance status, functional limitations due to age), leading to often poor tolerance of repeated chemotherapy courses and the unfavorable biology underlying this disease in older patients. Low dose Decitabine has shown very promising efficacy in high-risk MDS and is therefore a very promising approach also in older AML patients. Preliminary results from several centres have demonstrated excellent feasibility and good efficacy of this treatment. Therefore the investigators intend to investigate the effects of two drugs added onto low-dose Decitabine which have shown very promising synergistic effects in vitro and for which preliminary results indicate that the combination with low-dose Decitabine is very feasible.
Status | Completed |
Enrollment | 204 |
Est. completion date | February 2016 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: 1. Written informed consent obtained according to international guidelines and local law; 2. Male or female patients aged > 60 years without upper age limit; 3. Patients with primary or secondary AML according to WHO (= 20% blasts in the peripheral blood (pB) or bone marrow (BM)) who are not expected to benefit from standard remission-induction chemotherapy; 4. Patients with < 30 000 leukocytes/µl; 5. Performance status ECOG 0, 1, 2; 6. Creatinine < 2.0 mg/dl (unless leukemia-related); 7. Ability to understand the nature of the study and the study related procedures and to comply with them. Exclusion Criteria: 1. AML of FAB subtype M3; 2. Previous remission-induction chemotherapy for MDS or AML, previous allografting; 3. Previous treatment with DAC, 5-azacytidine, VPA or another HDAC inhibitor, or ATRA; 4. "Low-dose" chemotherapy (e.g. hydroxyurea, cytosine arabinoside (Ara-C), melphalan, clofarabine etc.) within 4 weeks prior to DAC treatment, except for cytoreduction of leukocytosis = 30 000/µl with hydroxyurea or Ara-C as proscribed by the study protocol (section 7.3 and 7.4); the patient must have recovered from all clinically relevant reversible non-hematologic toxicities; 5. Treatment with tyrosine kinase inhibitors, immunomodulating agents (IMIDS) or other investigational AML treatment within the last 4 weeks or in a time period of drug half-life x 5 (whatever is shorter) before the first administration of DAC; 6. Treatment with cytokines within previous 4 weeks; 7. Concomitant therapy which is considered relevant for the evaluation of efficacy or safety of the trial drug (i.e. other chemo- or immunotherapy); 8. Other malignancy requiring treatment (previous chemotherapy for other malignancies is not an exclusion criteria); 9. Cardiac insufficiency NYHA IV; 10. Insufficient hepatic function (bilirubin, AST or ALT > = 2.5 x Upper Limit of Normal (ULN)) (unless leukemia-related); 11. Fatal hepatic function disorder during treatment with valproic acid in siblings; 12. Hepatic porphyria; 13. Manifest serious pancreatic function disorder; 14. Plasmatic coagulation disorder not related to AML; 15. Known active hepatitis B or C; 16. Known HIV infection; 17. Other uncontrolled active infections; 18. Known allergy against soy beans or peanuts; 19. Psychiatric disorder that interferes with treatment; 20. Patient without legal capacity who is unable to understand the nature, significance and consequences of the study; 21. Known hypersensitivity to, or intolerance of, one of the trial drugs, another retinoid or the excipients of the trial drugs; 22. Concomitant use of any other investigational drug or participation in a clinical trial within the last thirty days before the start of this study; simultaneous participation in registry and diagnostic trials is allowed; 23. Female patients who are pregnant or breast feeding; 24. Fertile patients refusing to use safe contraceptive methods during the study (for details see clinical trial protocol section 5.3); 25. Known or persistent abuse of medication, drugs or alcohol. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Klinikum der Technischen Universität Aachen | Aachen | |
Germany | Vivantes Klinikum Neukölln | Berlin | |
Germany | Augusta-Kranken-Anstalt gGmbH | Bochum | |
Germany | Klinikum Braunschweig | Braunschweig | |
Germany | DIAKO Ev. Diakonie-Krankenhaus gGmbH | Bremen | |
Germany | Marien Hospital Düsseldorf | Düsseldorf | |
Germany | Universitätsklinikum Düsseldorf | Düsseldorf | |
Germany | Klinikum Esslingen GmbH | Esslingen | |
Germany | Universität Frankfurt | Frankfurt | |
Germany | Medizinische Universitätsklinik Freiburg | Freiburg | |
Germany | St. Marien-Hospital Hagen | Hagen | |
Germany | Universitätsklinikum Halle | Halle | |
Germany | Evangelisches Krankenhaus Hamm gGmbH | Hamm | |
Germany | Med. Hochschule Hannover | Hannover | |
Germany | Universitätsklinikum Jena | Jena | |
Germany | Ortenau Klinikum Lahr-Ettenheim | Lahr | |
Germany | Caritas Krankenhaus Lebach | Lebach | |
Germany | Universitätsklinikum Leipzig AöR | Leipzig | |
Germany | Klinikum Lüdenscheid | Lüdenscheid | |
Germany | Philipps-Universität Marburg | Marburg | |
Germany | TU München | München | |
Germany | University of Münster Medical Center | Münster | |
Germany | Ortenau Klinikum | Offenburg | |
Germany | Studienzentrum Onkologie Ravensburg | Ravensburg | |
Germany | Eberhard Karls Universität Tübingen | Tübingen | |
Germany | Universitätsklinikum Ulm | Ulm | |
Germany | Klinikum Villingen-Schwenningen | Villingen-Schwenningen |
Lead Sponsor | Collaborator |
---|---|
University Hospital Freiburg |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective best response rate (complete remission (CR) and partial remission (PR)) | 12 months after randomization of the last patient | No | |
Secondary | Overall best response rate (CR, PR and antileukemic effect (ALE)) | 12 months after randomization of the last patient | No | |
Secondary | progression-free survival (PFS) | 12 months after randomization of the last patient | No | |
Secondary | overall survival (OS) | 12 months after randomization of the last patient | No | |
Secondary | quality of life | until 4 weeks after study drug intake | No | |
Secondary | safety and toxicity | until 4 weeks after study drug intake | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |